Humoral Effect of SARS-CoV-2 mRNA Vaccination with Booster Dose in Solid Tumor Patients with Different Anticancer Treatments
Creators
- Chiara Piubelli1
- Matteo Valerio1
- Matteo Verzè1
- Fabrizio Nicolis1
- Carlotta Mantoan1
- Sonia Zamboni1
- Francesca Perandin1
- Eleonora Rizzi1
- Stefano Tais1
- Monica Degani1
- Sara Caldrer1
- Federico Giovanni Gobbi1
- Zeno Bisoffi1
- Stefania Gori1
Description
Cancer patients are at risk for serious complications in case of SARS-CoV-2 infection. In these patients, SARS-CoV-2 vaccination is strongly recommended, with the preferential use of mRNA vaccines. The antibody response in cancer patients is variable, depending on the type of cancer and antitumoral treatments.
In solid tumor patients, an antibody response similar to healthy subjects has been confirmed after the second dose. Only few studies explored the duration of immunization after the two doses and the effect of the third dose.
In our study, we explored a cohort of 273 solid tumor patients at different stages and treated with different anticancer therapies. Our analysis demonstrated that the persistence of the neutralizing antibody and the humoral response after the booster dose of vaccine was not dependent on either the tumor type, the stage, or the type of anticancer treatment.